Lataa...

Copper Chelation Inhibits BRAF(V600E)-driven Melanomagenesis and Counters Resistance to BRAF(V600E) and MEK1/2 Inhibitors

MEK1/2 and BRAF(V600E) inhibitors are used to treat BRAF(V600E)-positive melanoma, with other cancers under evaluation. Genetic perturbation of copper import or pharmacological reduction of copper with the clinical copper chelator TTM inhibits MEK1/2 kinase activity and reduces BRAF(V600E)-driven tu...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Cancer Res
Päätekijät: Brady, Donita C., Crowe, Matthew S., Greenberg, Danielle N., Counter, Christopher M.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2017
Aiheet:
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5690876/
https://ncbi.nlm.nih.gov/pubmed/28986383
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-16-1190
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!